Technology & Innovation

The pharma sector and the search for emotional branding

Asia

Asia

The pharmaceuticals industry is bland, defensive and fails to foster loyalty among its customers. These were some of the thoughts going through the mind of brand design guru Jonathan Sands, chairman of Elmwood, a design consultancy as he sat through the Economist Pharma Summit earlier this year.

"The more I listened to guys from big pharma the more I heard a recurring theme," says Mr Sands, whose consultancy has worked with some of the world&;s best-known retail, consumer and corporate brands. "They were worried about their patents running out, the rise of generic drugs."

Worse still, Mr Sands observed, was that the major companies appeared somewhat paranoid about their public image. "They thought that they were almost seen as being worse than bankers. I found it quite incredible—here was an industry doing research to help people have better lives, a front-foot industry talking on the back foot, relying on patents to protect their revenue streams," he says.

One issue facing the industry is that although pharma companies are well known, their medicines are not. In this regard, Mr Sands argues,
pharma is its own worst enemy—the portfolios at GlaxoSmithKline and AstraZeneca, for example, include Adartrel, Zyban, Accolate and Zomig. "These may have meaning internally in the corporation but are meaningless to the end-user, and nobody can identify one drug from the next from the packaging," Mr Sands argues.

Mr Sands believes that brands are like friends. "You can buy all sorts of smartphones, but you buy an iPhone for more than its functionality—you are part of the Apple Club. The iPhone 4 had antennae problems, but people still want to be part of the club."

In many of their largest markets, pharma companies are prohibited from marketing directly to patients, and regard doctors and governments as their primary targets. But patients—the ultimate consumers of medicine—are better informed than ever about their conditions and treatment options, and are playing an increasingly important and active role within healthcare systems. Pharma firms, Mr Sands says, could do worse than learn how to emulate companies in other sectors that have become successful because their customers love the brand.

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week